About Tilt Biotherapeutics
TILT Biotherapeutics, founded in 2013, is a leading company globally working in the area of enabling tumor T-cell therapy with oncolytic viruses. The company’s patented technology is used to enhance tumor infiltrating lymphocyte (TIL), chimeric antigen receptor (CAR-T) and checkpoint inhibiting antibody therapy. TILT has secured almost 10M€ in funding and is now setting up phase I clinical trials, where its approach is further evaluated in cancer patients.
State of Ownership
Business Development Executive, Nature Publishing Group, Springer Nature
Clinical trials Analyst at CBIO/NUDFAC-UFPE, CBIO/NUDFAC-UFPE
Sales Account Executive, Springer Nature